ArticleLeukemia2025

Rituximab, high-dose methotrexate plus orelabrutinib as induction therapy in newly diagnosed primary central nervous system lymphoma.

Shi-Hua Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.